AR070951A1 - INDANO COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM - Google Patents
INDANO COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEMInfo
- Publication number
- AR070951A1 AR070951A1 ARP080104619A ARP080104619A AR070951A1 AR 070951 A1 AR070951 A1 AR 070951A1 AR P080104619 A ARP080104619 A AR P080104619A AR P080104619 A ARP080104619 A AR P080104619A AR 070951 A1 AR070951 A1 AR 070951A1
- Authority
- AR
- Argentina
- Prior art keywords
- ethyl
- indan
- methoxy
- propionamide
- phenyl
- Prior art date
Links
- 230000004075 alteration Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 230000001193 melatoninergic effect Effects 0.000 title abstract 2
- 240000001546 Byrsonima crassifolia Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 6-methoxy-3-methyl-indan-1-yl Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 2
- 206010022437 insomnia Diseases 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- YTJDTOZHLOJSQD-UHFFFAOYSA-N 1-ethyl-3-[2-(6-methoxy-3-methyl-2,3-dihydro-1h-inden-1-yl)ethyl]urea Chemical compound C1=C(OC)C=C2C(CCNC(=O)NCC)CC(C)C2=C1 YTJDTOZHLOJSQD-UHFFFAOYSA-N 0.000 abstract 1
- 125000003836 4-phenylbutoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 210000002249 digestive system Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 150000002468 indanes Chemical class 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- BPOPGICACIINTC-UHFFFAOYSA-N n-[2-(2-benzyl-6-methoxy-2,3-dihydro-1h-inden-1-yl)ethyl]acetamide Chemical compound CC(=O)NCCC1C2=CC(OC)=CC=C2CC1CC1=CC=CC=C1 BPOPGICACIINTC-UHFFFAOYSA-N 0.000 abstract 1
- DAXOFOGDIPLUAS-UHFFFAOYSA-N n-[2-(2-ethyl-6-methoxy-2,3-dihydro-1h-inden-1-yl)ethyl]propanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CC)C(CC)CC2=C1 DAXOFOGDIPLUAS-UHFFFAOYSA-N 0.000 abstract 1
- ABLCLDGSSBMYHP-UHFFFAOYSA-N n-[2-(5-bromo-6-methoxy-2,3-dihydro-1h-inden-1-yl)ethyl]propanamide Chemical compound BrC1=C(OC)C=C2C(CCNC(=O)CC)CCC2=C1 ABLCLDGSSBMYHP-UHFFFAOYSA-N 0.000 abstract 1
- XLQWMAYNSQHNTQ-UHFFFAOYSA-N n-[2-(6-methoxy-2,3-dihydro-1h-inden-1-yl)ethyl]butanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CCC)CCC2=C1 XLQWMAYNSQHNTQ-UHFFFAOYSA-N 0.000 abstract 1
- VJGZYRXNBVKENO-UHFFFAOYSA-N n-[2-(6-methoxy-2,3-dihydro-1h-inden-1-yl)propyl]acetamide Chemical compound COC1=CC=C2CCC(C(C)CNC(C)=O)C2=C1 VJGZYRXNBVKENO-UHFFFAOYSA-N 0.000 abstract 1
- GZCHRFYQOHIXIN-UHFFFAOYSA-N n-[2-(6-methoxy-2-phenyl-2,3-dihydro-1h-inden-1-yl)ethyl]propanamide Chemical compound C1C2=CC=C(OC)C=C2C(CCNC(=O)CC)C1C1=CC=CC=C1 GZCHRFYQOHIXIN-UHFFFAOYSA-N 0.000 abstract 1
- YKFPGQHPECZDRX-UHFFFAOYSA-N n-[2-(6-methoxy-2-propyl-2,3-dihydro-1h-inden-1-yl)ethyl]propanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CC)C(CCC)CC2=C1 YKFPGQHPECZDRX-UHFFFAOYSA-N 0.000 abstract 1
- ZSLNGWRYJDPHFU-UHFFFAOYSA-N n-[2-(6-methoxy-3-methyl-2,3-dihydro-1h-inden-1-yl)ethyl]-2,2-dimethylpropanamide Chemical compound COC1=CC=C2C(C)CC(CCNC(=O)C(C)(C)C)C2=C1 ZSLNGWRYJDPHFU-UHFFFAOYSA-N 0.000 abstract 1
- UTLUYKNRQRVZOP-UHFFFAOYSA-N n-[2-(6-methoxy-3-methyl-2,3-dihydro-1h-inden-1-yl)ethyl]propanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CC)CC(C)C2=C1 UTLUYKNRQRVZOP-UHFFFAOYSA-N 0.000 abstract 1
- GMJCXVBPBIFQGB-UHFFFAOYSA-N n-[2-(6-methoxy-5-phenyl-2,3-dihydro-1h-inden-1-yl)ethyl]propanamide Chemical compound COC=1C=C2C(CCNC(=O)CC)CCC2=CC=1C1=CC=CC=C1 GMJCXVBPBIFQGB-UHFFFAOYSA-N 0.000 abstract 1
- FZQMCTLMEHMJKU-UHFFFAOYSA-N n-[2-(6-methoxy-5-pyridin-4-yl-2,3-dihydro-1h-inden-1-yl)ethyl]propanamide Chemical compound COC=1C=C2C(CCNC(=O)CC)CCC2=CC=1C1=CC=NC=C1 FZQMCTLMEHMJKU-UHFFFAOYSA-N 0.000 abstract 1
- FSYHPGVBCVTEMI-UHFFFAOYSA-N n-[2-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methoxy-2,3-dihydro-1h-inden-1-yl]ethyl]propanamide Chemical compound COC=1C=C2C(CCNC(=O)CC)CCC2=CC=1C=1C(C)=NOC=1C FSYHPGVBCVTEMI-UHFFFAOYSA-N 0.000 abstract 1
- QGTIWKUTXUFHHK-UHFFFAOYSA-N n-[2-[6-(2-phenylethoxy)-2,3-dihydro-1h-inden-1-yl]ethyl]propanamide Chemical compound C1=C2C(CCNC(=O)CC)CCC2=CC=C1OCCC1=CC=CC=C1 QGTIWKUTXUFHHK-UHFFFAOYSA-N 0.000 abstract 1
- FCUGDEHQHFGQHX-UHFFFAOYSA-N n-[2-[6-(4-phenylbutoxy)-2,3-dihydro-1h-inden-1-yl]ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)CCC2=CC=C1OCCCCC1=CC=CC=C1 FCUGDEHQHFGQHX-UHFFFAOYSA-N 0.000 abstract 1
- IJVLXTKULJLPKP-UHFFFAOYSA-N n-[2-[6-(4-phenylbutoxy)-2,3-dihydro-1h-inden-1-yl]ethyl]propanamide Chemical compound C1=C2C(CCNC(=O)CC)CCC2=CC=C1OCCCCC1=CC=CC=C1 IJVLXTKULJLPKP-UHFFFAOYSA-N 0.000 abstract 1
- IQZAEHNCIYPJIZ-UHFFFAOYSA-N n-[2-[6-methoxy-5-(4-methoxyphenyl)-2,3-dihydro-1h-inden-1-yl]ethyl]propanamide Chemical compound COC=1C=C2C(CCNC(=O)CC)CCC2=CC=1C1=CC=C(OC)C=C1 IQZAEHNCIYPJIZ-UHFFFAOYSA-N 0.000 abstract 1
- KCFJZLDMRSQDNA-UHFFFAOYSA-N n-[2-[6-methoxy-5-(4-methylphenyl)-2,3-dihydro-1h-inden-1-yl]ethyl]propanamide Chemical compound COC=1C=C2C(CCNC(=O)CC)CCC2=CC=1C1=CC=C(C)C=C1 KCFJZLDMRSQDNA-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000012672 seasonal affective disease Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000022925 sleep disturbance Diseases 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Compuestos de indano que se seleccionan del grupo consistente en: 1) N-[2-(6-metoxi-indan-1-il)-propil]-acetamida; 2) N-[2-(2-bencil-6-metoxi-indan-1-il)etil]-acetamida, 3) N-[2-(2-etil-6-metoxi-indan-1-il)-etil]-propionamida, 4) N-[2-(6-metoxi-2-propil-indan-1-il)-etil]-propionamida, 5) N-[2-(6-metoxi-2-fenil-indan-1-il)-etil]-propionamida, 6) N-[2-(6-metoxi-indan-1-il)etil]-butiramida, 7) N-[2-(6-metoxi-3-metil-indan-1-il)-etil]-propionamida, 8) N-[2-(6-metoxi-3-metil-indan-1-il)]-etil-acetamida, 9) 1-etil-3-[2-(6-metoxi-3-metil-indan-1-il)-etil]-urea, 10) N-[2-(6-metoxi-3-metil-indan-1-il)-etil]-2,2-dimetil-propionamida, 11) -2-(6-metoxi-3-metil-indan-1-il)-etil]-ciclopropancarboxamida, 12) N-[2-(5-bromo-6-metoxi-indan-1-il)-etil]-propionamida, 13) N-[2-(6-metoxi-5-fenil-indan-1-il)-etil]-propionamida, 14) N-[2-(6-metoxi-5-p-tolil-indan-1-il)-etil]-propionamida, 15) N-[2-(6-metoxi-5-(4-metoxi-fenil)-indan-1-il)-etil]-propionamida, 16) N-{2-[5-(3,5-dimetil-isoxazol-4-il)-6-metoxi-indan-1-il]-etil}-propionamida, 17) N-[2-(6-metoxi-5-piridin-4-il-indan-1-il)-etil]-propionamida, 18) N-[2-(5-furan-2-il-6-metoxi-indan-1-il)-etil]-propionamida, 19) N-[2-(6-fenetiloxi-indan-1-il)-etil]-propionamida, 20) N-{2-[6-(4-fenil-butoxi)-indan-1-il]-etil}-propionamida, 21) N-{2-[6-(4-fenil-butoxi)-indan-1-il]-etil}-acetamida, 22) 1-etil-3-{2-[6-(4-fenil-butoxi)-indan-1-il]-etil]-urea y 23) {2-[6-(4-fenil-butoxi)-indan-1-il]-etil}-carbamato de metilo y sus sales e hidratos farmacéuticamente aceptables. Sus usos para la preparacion de un medicamento y para el tratamiento o la prevencion de las alteraciones melatoninérgicas, seleccionadas del grupo de: la depresion, el stress, las alteraciones del sueno, la ansiedad, los trastornos afectivos estacionales, la patología cardiovascular, la patología del sistema digestivo, el insomnio o la fatiga debidos al ôjet lagö, la esquizofrenia, los ataques de pánico, la melancolía, las alteraciones del apetito, la obesidad, el insomnio, las enfermedades psicoticas, la epilepsia, la diabetes, la enfermedad de Parkinson, a demencia senil, las alteraciones asociadas con el envejecimiento normal o patologico, la migrana, la pérdida de memoria, la enfermedad de Alzheimer y las alteraciones de la circulacion cerebral.Indane compounds that are selected from the group consisting of: 1) N- [2- (6-methoxy-indan-1-yl) -propyl] -acetamide; 2) N- [2- (2-Benzyl-6-methoxy-indan-1-yl) ethyl] -acetamide, 3) N- [2- (2-ethyl-6-methoxy-indan-1-yl) - ethyl] -propionamide, 4) N- [2- (6-methoxy-2-propyl-indan-1-yl) -ethyl] -propionamide, 5) N- [2- (6-methoxy-2-phenyl-indan -1-yl) -ethyl] -propionamide, 6) N- [2- (6-methoxy-indan-1-yl) ethyl] -butyramide, 7) N- [2- (6-methoxy-3-methyl- indan-1-yl) -ethyl] -propionamide, 8) N- [2- (6-methoxy-3-methyl-indan-1-yl)] - ethyl-acetamide, 9) 1-ethyl-3- [2 - (6-methoxy-3-methyl-indan-1-yl) -ethyl] -urea, 10) N- [2- (6-methoxy-3-methyl-indan-1-yl) -ethyl] -2, 2-dimethyl-propionamide, 11) -2- (6-methoxy-3-methyl-indan-1-yl) -ethyl] -cyclopropancarboxamide, 12) N- [2- (5-bromo-6-methoxy-indan- 1-yl) -ethyl] -propionamide, 13) N- [2- (6-methoxy-5-phenyl-indan-1-yl) -ethyl] -propionamide, 14) N- [2- (6-methoxy- 5-p-tolyl-indan-1-yl) -ethyl] -propionamide, 15) N- [2- (6-methoxy-5- (4-methoxy-phenyl) -indan-1-yl) -ethyl] - propionamide, 16) N- {2- [5- (3,5-dimethyl-isoxazol-4-yl) -6-methoxy-indan-1-yl] -ethyl} -propionamide, 17) N- [2- ( 6-methoxy-5-pyridin-4-yl-indan-1-yl) -ethyl] -propionamide, 18) N- [2- (5-furan-2- il-6-methoxy-indan-1-yl) -ethyl] -propionamide, 19) N- [2- (6-phenethyloxy-indan-1-yl) -ethyl] -propionamide, 20) N- {2- [ 6- (4-phenyl-butoxy) -indan-1-yl] -ethyl} -propionamide, 21) N- {2- [6- (4-phenyl-butoxy) -indan-1-yl] -ethyl} - acetamide, 22) 1-ethyl-3- {2- [6- (4-phenyl-butoxy) -indan-1-yl] -ethyl] -urea and 23) {2- [6- (4-phenyl-butoxy ) -indan-1-yl] -ethyl} -methylcarbamate and its pharmaceutically acceptable salts and hydrates. Its uses for the preparation of a drug and for the treatment or prevention of melatoninergic disorders, selected from the group of: depression, stress, sleep disturbances, anxiety, seasonal affective disorders, cardiovascular pathology, pathology of the digestive system, insomnia or fatigue due to ôjet lagö, schizophrenia, panic attacks, melancholy, appetite disturbances, obesity, insomnia, psychotic diseases, epilepsy, diabetes, Parkinson's disease , to senile dementia, the alterations associated with normal or pathological aging, migraine, memory loss, Alzheimer's disease and alterations of cerebral circulation.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200702797A ES2324849A1 (en) | 2007-10-25 | 2007-10-25 | Indane compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070951A1 true AR070951A1 (en) | 2010-05-19 |
Family
ID=40347968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080104619A AR070951A1 (en) | 2007-10-25 | 2008-10-23 | INDANO COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM |
Country Status (6)
Country | Link |
---|---|
AR (1) | AR070951A1 (en) |
CL (1) | CL2008003138A1 (en) |
ES (1) | ES2324849A1 (en) |
TW (1) | TW200934477A (en) |
UY (1) | UY31422A1 (en) |
WO (1) | WO2009053443A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2758041B1 (en) | 2011-09-20 | 2021-01-13 | Basf Se | Low-molecular modulators of the cold-menthol receptor trpm8 and use of same |
CN103193668B (en) * | 2013-03-19 | 2016-01-20 | 华东师范大学 | Chiral indan derivant and its production and use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654325A (en) * | 1993-11-18 | 1997-08-05 | Eli Lilly And Company | Melatonin derivatives for use in treating sleep disorders |
EP0781271B1 (en) * | 1994-09-12 | 2000-06-07 | Takeda Chemical Industries, Ltd. | Benzocycloalkene compounds, their production and use |
US5661186A (en) * | 1995-02-24 | 1997-08-26 | Bristol-Myers Squibb Co. | Tetralinyl-and indanyl-ethylamides |
EP1550655A1 (en) * | 1996-03-08 | 2005-07-06 | Takeda Pharmaceutical Company Limited | Bicyclic intermediates |
-
2007
- 2007-10-25 ES ES200702797A patent/ES2324849A1/en not_active Withdrawn
-
2008
- 2008-10-23 WO PCT/EP2008/064392 patent/WO2009053443A2/en active Application Filing
- 2008-10-23 AR ARP080104619A patent/AR070951A1/en unknown
- 2008-10-24 CL CL2008003138A patent/CL2008003138A1/en unknown
- 2008-10-24 TW TW097140813A patent/TW200934477A/en unknown
- 2008-10-24 UY UY31422A patent/UY31422A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009053443A2 (en) | 2009-04-30 |
UY31422A1 (en) | 2009-04-30 |
ES2324849A1 (en) | 2009-08-17 |
CL2008003138A1 (en) | 2009-03-06 |
WO2009053443A3 (en) | 2009-09-24 |
TW200934477A (en) | 2009-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2611437C2 (en) | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use | |
CL2012001501A1 (en) | Co-crystal consisting of agomelatine and an organic acid that has a solid state at room temperature; preparation procedures; pharmaceutical composition; and use in the treatment of disorders of the melatoninergic system such as stress, sleep disorders and generalized anxiety disorders, among others. | |
HRP20170095T1 (en) | New crystalline form iii of agomelatin, the process for its preparation and pharmaceutical compositions containing it | |
HRP20161672T1 (en) | New crystalline form vi of agomelatine, method of preparation and pharmaceutical compositions thereof | |
JP7074750B2 (en) | Carbamoyl phenylalaninol compounds and their use | |
CN101790374A (en) | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted | |
HRP20201405T1 (en) | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar | |
TWI453013B (en) | Use of n-(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-3,3-dimethyl-butyramide and medicament comprising said compound | |
CL2011000137A1 (en) | Use of compounds derived from 4,5-dihydro-oxazol-2-ylamine to treat anxiety disorders, bipolar disorders, schizophrenia, neurological diseases, epilepsy, migraine, metabolic disorders, cardiovascular disorders, among others; compounds derived from 4,5-dihydroxazol-2-ylamino; synthesis process | |
CN1248966A (en) | Aminobenzophenones as inhibitors of interleukin and TNF | |
NI200700084A (en) | USE OF AGOMELATINE FOR THE OBTAINING OF MEDICINES FOR THE TREATMENT OF THE GENERALIZED ANXIETY DISORDER | |
AR069003A1 (en) | INDOLINA COMPOUNDS, THEIR USES IN THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USE OF THE PHARMACEUTICAL COMPOSITION TO PREPARE A MEDICINAL PRODUCT | |
RU2012121684A (en) | OXAZOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISEASES | |
AR070951A1 (en) | INDANO COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
JP2015521642A5 (en) | ||
NO20084865L (en) | Treatment of pain disorders with trans 4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydro-1-naphthalenamine and its formamide | |
AR069004A1 (en) | COMPOUNDS OF 2,3-DIHIDRO-BENZOFURAN ITS USES FOR THE PREPARATION OF MEDICINES AND ITS USES FOR THE TREATMENT OF MELATONINERGIC ALTERATIONS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
JP2011529477A5 (en) | ||
JP2011500763A5 (en) | ||
ES2363565T3 (en) | USEFUL REPLACED ACETOPHENONS AS PDE INHIBITORS 4. | |
AR070003A1 (en) | NAFTALENIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
JP2015521643A5 (en) | ||
AR069002A1 (en) | PHENYL PIRROLIDINE COMPOUNDS, THEIR USES FOR THE PREPARATION OF MEDICINES AND THEIR USES FOR THE TREATMENT OF MELATONINERGIC CHANGES, AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM | |
HRP20090632T1 (en) | New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them | |
AR070004A1 (en) | NAFTALENIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |